Jiangsu Apon Medical Technology Co. Ltd. Class A

Jiangsu Apon Medical Technology Co. Ltd. Class A

SSZSE:300753
18.84
CNY
-1.07
(-5.37%)
-0.27EPS
2.60BMarket Cap
Apr 29Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.27
1.22
2.11
2.62
3.16
3.01
3.52
3.66
2.57
3.35
3.2
2.71
2.55
Basic EPS, GAAP
0.33
0.23
0.51
0.62
0.74
0.81
0.77
0.43
-0.6
0.07
0.09
-0.19
-0.23
Free Cash Flow per Basic Share
- -
0.28
0.6
0.55
0.18
0.15
0.38
-0.17
-0.39
-0.43
0.04
-0.05
- -
Dividend per Share
0.04
0.06
0.17
0.11
- -
0.26
0.26
0.25
0.01
0.01
0.08
0.08
0.01
Book Value per Share
0.82
1.49
2.37
2.88
4.8
5.35
5.87
6.19
5.44
5.52
5.55
5.3
5.16
Tangible Book Value per Share
0.8
1.47
1.85
2.3
4.41
4.88
5.3
5.37
4.74
4.83
4.83
4.33
4.2
Basic Weighted Avg Shares
95
126
94
94
94
126
126
126
126
126
126
126
126
Sales/Revenue/Turnover
120
154
198
247
298
380
443
461
324
422
404
342
322
Operating Margin (%)
29.92
18.39
23.51
28.2
29.05
25.22
24.41
12.88
-22.21
5.78
7.14
-7.57
-9.66
Depreciation Expense
- -
3
9
9
9
10
10
15
20
18
21
21
- -
Net Income, GAAP
31
29
48
58
70
102
97
54
-76
8
11
-24
-29
Effective Tax Rate (%)
17.52
11.17
14.23
13.7
15.11
12.72
13.44
3.58
- -
38.81
48.53
- -
- -
Profit Margin (%)
26.08
18.82
24.06
23.46
23.52
26.96
21.88
11.72
-23.46
1.96
2.67
-7.02
-9.08
Working Capital
47
93
136
181
446
459
438
408
298
312
333
243
153
LT Debt
- -
- -
- -
- -
- -
- -
4
40
35
31
28
25
23
Total Equity
81
145
230
279
613
675
740
781
687
697
708
680
662
Return on Invested Capital (%)
- -
19.29
21.11
23.17
16.09
16.18
13.67
6.85
- -
1.12
1.56
- -
- -
Return on Capital (%)
- -
24.25
24.41
21.84
15.27
15.81
13.68
7.15
- -
1.31
1.57
- -
- -
Return on Common Equity (%)
- -
26.45
26.14
23.37
15.99
15.99
13.71
7.12
-10.37
1.2
1.55
-3.51
-4.42

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
74
60
104
LT Borrowings
- -
- -
- -
LT Finance Leases
25
23
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
126
126
126
Market Capitalization
3,464
2,386
2,604

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
334
313
303
Cash, Cash Equivalents & STI
97
84
81
Accounts Receivable, Net
133
128
126
Inventories
59
62
59
Total Current Liabilities
115
101
150
Payables & Accruals
- -
- -
- -
ST Debt
74
60
104
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.13%
-1.49%
-3.98%
Free Cash Flow
-17.81%
-65.41%
-211.92%
Net Income, GAAP
-53.93%
-137.52%
-322.4%
Sales/Revenue/Turnover
10.35%
-2.99%
-15.3%
Total Cash Common Dividend
- -
128.13%
4.94%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
88
92
95
129
404
2025
65
94
- -
90
342
2026
68
80
83
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.06
-0.04
0.06
0.09
2025
-0.14
-0.01
- -
-0.1
-0.19
2026
-0.03
-0.04
-0.05
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.07
- -
- -
0.08
2025
- -
0.07
- -
- -
0.08
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zhi Hui Zhang
Full Time Employees
592
Sector
Health technology
Industry
Medical specialties
Address
East side of Yongtong Avenue Nantong JS China 226400
IPO Date
Dec 13, 2018
Business
Jiangsu Apon Medical Technology Co., Ltd. (300753.SZ) develops, produces, and sells medical devices focused on anesthesia and analgesia, chronic pain management, and nasal airway care; its principal products include microcomputer fully automatic infusion pumps, disposable infusion pumps, portable electric infusion pumps, wireless analgesia management systems, pulse oximeters, new generation anesthesia depth monitors, internal heat needle therapy devices, low-frequency treatment devices, shock wave therapy devices, physiological seawater nasal sprays, hypertonic buffered seawater nasal care sprayers, weak acid buffered physiological seawater nasal sprays, fixed snore stoppers, and seawater for upper respiratory tract indications. Founded in October 2001 and headquartered in Nantong, Jiangsu Province, China, the company operates primarily in the Chinese market through over 10 subsidiaries in locations including Shanghai, Shenzhen, Hangzhou, Sichuan Province, and Hunan Province, employing over 600 people; it listed on the Shenzhen Stock Exchange GEM board in December 2018. Recent developments include selection as a national-level "little giant" enterprise in January 2023, recognition as an "Advanced Smart Factory in Jiangsu Province" in 2025, launch of the new generation anesthesia depth monitor in early 2023, and acquisitions such as Shenzhen BSK Medical Equipment Co., Ltd. in April 2022 to expand into chronic pain management and Sichuan Jinjiazheng Medical Instrument Co., Ltd. in November 2022 to enter anesthesia depth monitoring.